unicycive logo.png
Unicycive Reports Key Findings of UNI-494 Efficacy in Preclinical Animal Model of Acute Kidney Injury (AKI)
September 07, 2022 07:00 ET | Unicycive Therapeutics, Inc.
Established animal model of AKI showed a statistically significant reduction of a key biomarker of kidney injury when treated with UNI-494 AKI remains a serious unmet medical need with no FDA...
unicycive logo.png
Unicycive Announces Multiple Abstracts Selected for Presentation at American Society of Nephrology’s Kidney Week 2022
August 24, 2022 07:00 ET | Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today...
Unicycive Reports Key Findings from Independent Renal Dietitian Survey
July 26, 2022 07:00 ET | Unicycive Therapeutics, Inc.
Hyperphosphatemia ranked as area of greatest unmet need Highlights most appealing benefits of Renazorb as efficacy/potency and lower pill burden Confirms patient preference for pills that are...
Unicycive Therapeutics, Inc.
Unicycive Reports Key Findings from Market Research with Nephrologists
July 20, 2022 07:12 ET | Unicycive Therapeutics, Inc.
Renazorb product profile rated as best-in-class phosphate binder Nephrologists report high prescribing intent for Renazorb pending FDA approval LOS ALTOS, Calif., July 20, 2022 (GLOBE...